Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRL | P40313 | 14/20 | 0.87 |
| ▸ | TMPRSS11D | O60235 | 7/20 | 0.87 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.63 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.63 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.63 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.63 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.63 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.63 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.63 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.63 |
| ▸ | CTSB | P07858 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.63 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.63 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.63 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.63 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.63 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.63 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.63 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8143396 | 1.00 | CTRL (0.87) | CTRLTMPRSS11DPSMB5PSMB8PSMB11 | |
| SCHEMBL14538012 | 1.00 | CTRL (0.87) | CTRLTMPRSS11DPSMB5PSMB8PSMB11 | |
| SCHEMBL8135866 | 0.96 | CTRL (0.88) | CTRLTMPRSS11DPSMB5PSMB8PSMB11 | |
| SCHEMBL19289569 | 0.96 | CTRL (0.88) | CTRLTMPRSS11DPSMB5PSMB8PSMB11 | |
| SCHEMBL14538051 | 0.96 | CTRL (0.88) | CTRLTMPRSS11DPSMB5PSMB8PSMB11 | |
| SCHEMBL19341742 | 0.96 | CTRL (0.88) | CTRLTMPRSS11DPSMB5PSMB8PSMB11 | |
| SCHEMBL8123039 | 0.94 | CTRL (0.90) | CTRLTMPRSS11DPSMB5PSMB8PSMB11 | |
| SCHEMBL22423754 | 0.94 | CTRL (0.90) | CTRLTMPRSS11DPSMB5PSMB8PSMB11 | |
| SCHEMBL19289605 | 0.94 | CTRL (0.90) | CTRLTMPRSS11DPSMB5PSMB8PSMB11 | |
| SCHEMBL8135868 | 0.94 | CTRL (0.90) | CTRLTMPRSS11DPSMB5PSMB8PSMB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289606-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20190224270-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2019-07-25 | — | — | US | disclosed |
| EP-3021862-B1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2017-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289606-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | CTRL 1320/4885TMPRSS11D 500/4885PSMB5 57/4885 |
| US-20190224270-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | CTRL 1320/4885TMPRSS11D 500/4885PSMB5 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.